DK2318028T3 - Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer - Google Patents
Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer Download PDFInfo
- Publication number
- DK2318028T3 DK2318028T3 DK09770571.9T DK09770571T DK2318028T3 DK 2318028 T3 DK2318028 T3 DK 2318028T3 DK 09770571 T DK09770571 T DK 09770571T DK 2318028 T3 DK2318028 T3 DK 2318028T3
- Authority
- DK
- Denmark
- Prior art keywords
- activia
- activin
- solvable
- antagonists
- applications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13336808P | 2008-06-26 | 2008-06-26 | |
| PCT/US2009/003838 WO2009158033A2 (en) | 2008-06-26 | 2009-06-26 | Antagonists of activin-actriia and uses for increasing red blood cell levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2318028T3 true DK2318028T3 (da) | 2020-05-04 |
Family
ID=41445146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09770571.9T DK2318028T3 (da) | 2008-06-26 | 2009-06-26 | Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer |
Country Status (10)
| Country | Link |
|---|---|
| EP (4) | EP2303917B1 (enExample) |
| JP (8) | JP5773868B2 (enExample) |
| KR (4) | KR20110031951A (enExample) |
| CN (2) | CN102131515B (enExample) |
| AU (4) | AU2009262968A1 (enExample) |
| CA (3) | CA2729098C (enExample) |
| DK (1) | DK2318028T3 (enExample) |
| ES (2) | ES2852699T3 (enExample) |
| NZ (2) | NZ590326A (enExample) |
| WO (2) | WO2009158015A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| KR102170682B1 (ko) * | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| AU2015203400A1 (en) * | 2009-08-13 | 2015-07-16 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CA2817008A1 (en) * | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| JP6401172B2 (ja) * | 2012-10-24 | 2018-10-10 | セルジーン コーポレイション | 貧血の治療方法 |
| RU2678117C2 (ru) * | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| CA2898121A1 (en) * | 2013-01-25 | 2014-07-31 | Shire Human Genetic Therapies, Inc. | Follistatin in treating duchenne muscular dystrophy |
| EP3131931B1 (en) * | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| JP6568110B2 (ja) * | 2014-06-04 | 2019-08-28 | アクセルロン ファーマ， インコーポレイテッド | フォリスタチンポリペプチドによる障害の処置のための方法および組成物 |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| EP3227675B1 (en) | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| CN113683708A (zh) * | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| JP7072507B2 (ja) | 2015-11-23 | 2022-05-20 | アクセルロン ファーマ インコーポレイテッド | 眼の障害を処置するための方法 |
| US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| AU2017338916B2 (en) | 2016-10-05 | 2022-03-24 | Acceleron Pharma Inc. | Variant ActRIIB proteins and uses thereof |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3043184A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| EP3706777B1 (en) | 2017-11-09 | 2024-05-22 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| IL320014A (en) | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| IL278546B2 (en) * | 2018-05-09 | 2026-03-01 | Keros Therapeutics Inc | Activin receptor type IIA variants and methods of using them |
| JP7462907B2 (ja) | 2018-11-15 | 2024-04-08 | 三菱ケミカル株式会社 | 改変型アクチビンａ |
| AU2020334924A1 (en) * | 2019-08-22 | 2022-04-07 | The Regents Of The University Of California | UBE3A for the treatment of Angelman syndrome |
| EP4121078A4 (en) | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| CN119529092A (zh) * | 2021-09-03 | 2025-02-28 | 来凯医药科技(上海)有限公司 | 抗acvr2a抗体及其用途 |
| CN122404564A (zh) * | 2025-01-15 | 2026-07-17 | 沈阳三生制药有限责任公司 | 一种ActRⅡB融合蛋白及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1265208A (en) | 1915-09-07 | 1918-05-07 | Edward C Kahn | Liquid-fuel burner. |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| EP0548276A4 (en) * | 1990-09-13 | 1993-12-29 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
| US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
| US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
| US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
| EP0830459B1 (en) | 1995-04-11 | 2007-01-24 | The General Hospital Corporation | Reverse two-hybrid systems |
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| US6953662B2 (en) * | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
| AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| US6468543B1 (en) * | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| WO2002094864A2 (en) * | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| US6855344B2 (en) * | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2005028517A2 (en) * | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| JP2008507288A (ja) * | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| BRPI0618947B1 (pt) * | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| AU2007249827A1 (en) * | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| UA96452C2 (uk) * | 2006-07-13 | 2011-11-10 | Басф Се | Зв'язувальний засіб, термопластична маса, що містить зв'язувальний засіб, формований виріб на основі термопластичної маси та спосіб одержання термопластичної маси та формованих виробів |
| MX2009000722A (es) * | 2006-07-21 | 2009-06-11 | Lyne Lab | Composiciones liquidas de acetato de calcio. |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| US7547781B2 (en) * | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| CA2672758C (en) * | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| CA2699936A1 (en) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| DE102008016742B4 (de) * | 2008-03-31 | 2010-01-14 | Thyssenkrupp Presta Ag | Lenksäule für ein Kraftfahrzeug |
-
2009
- 2009-06-26 KR KR1020117001139A patent/KR20110031951A/ko not_active Withdrawn
- 2009-06-26 EP EP09770553.7A patent/EP2303917B1/en active Active
- 2009-06-26 CA CA2729098A patent/CA2729098C/en active Active
- 2009-06-26 CA CA2729054A patent/CA2729054C/en active Active
- 2009-06-26 ES ES09770553T patent/ES2852699T3/es active Active
- 2009-06-26 NZ NZ590326A patent/NZ590326A/xx unknown
- 2009-06-26 AU AU2009262968A patent/AU2009262968A1/en not_active Abandoned
- 2009-06-26 KR KR1020177008278A patent/KR102024444B1/ko active Active
- 2009-06-26 WO PCT/US2009/003808 patent/WO2009158015A2/en not_active Ceased
- 2009-06-26 EP EP09770571.9A patent/EP2318028B1/en active Active
- 2009-06-26 CA CA3049354A patent/CA3049354A1/en not_active Abandoned
- 2009-06-26 JP JP2011516323A patent/JP5773868B2/ja active Active
- 2009-06-26 KR KR1020197012336A patent/KR20190049912A/ko not_active Ceased
- 2009-06-26 KR KR1020217011646A patent/KR20210047374A/ko not_active Ceased
- 2009-06-26 NZ NZ602471A patent/NZ602471A/en unknown
- 2009-06-26 ES ES09770571T patent/ES2791699T3/es active Active
- 2009-06-26 WO PCT/US2009/003838 patent/WO2009158033A2/en not_active Ceased
- 2009-06-26 CN CN200980133280.0A patent/CN102131515B/zh active Active
- 2009-06-26 EP EP19191414.2A patent/EP3620795A1/en not_active Withdrawn
- 2009-06-26 DK DK09770571.9T patent/DK2318028T3/da active
- 2009-06-26 CN CN201710403739.0A patent/CN107252486B/zh active Active
- 2009-06-26 EP EP20195139.9A patent/EP3804746A1/en not_active Withdrawn
-
2014
- 2014-02-07 JP JP2014022289A patent/JP2014088438A/ja not_active Withdrawn
-
2015
- 2015-07-23 JP JP2015145499A patent/JP2015187180A/ja not_active Withdrawn
-
2016
- 2016-05-12 AU AU2016203098A patent/AU2016203098B2/en active Active
- 2016-11-11 JP JP2016220297A patent/JP2017036331A/ja not_active Withdrawn
-
2018
- 2018-06-08 AU AU2018204105A patent/AU2018204105A1/en not_active Abandoned
- 2018-09-03 JP JP2018164195A patent/JP6643432B2/ja active Active
- 2018-09-03 JP JP2018164196A patent/JP2018184484A/ja not_active Withdrawn
-
2019
- 2019-12-23 JP JP2019231523A patent/JP2020041002A/ja not_active Withdrawn
-
2020
- 2020-08-17 AU AU2020220046A patent/AU2020220046A1/en not_active Abandoned
-
2021
- 2021-10-28 JP JP2021176418A patent/JP2022023184A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287990A (en) | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels | |
| DK2598483T3 (da) | Ampk-aktiverende heterocykliske forbindelser og fremgangsmåder til anvendelse af disse | |
| DK2205731T3 (da) | Anvendelse og fremstilling af citrat-stabile, neutrale metalloproteaser | |
| EP2456787A4 (en) | CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| DK2691443T3 (da) | Konjugerede lipomerer og anvendelser af disse | |
| DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
| DK3202460T3 (da) | Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme | |
| DK3321355T3 (da) | Fremgangsmåder og sammensætninger til klinisk afledning af en allogen celle og terapeutiske anvendelser | |
| DK2646444T3 (da) | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer | |
| DK3213738T3 (da) | Sammensætninger og fremgangsmåder til målrettet termomodulering | |
| DK2557517T3 (da) | Bestemmelse af ubalance i nukleinsyresekvens | |
| DK2459743T3 (da) | Sæt af oligonukleotidprober såvel som fremgangsmåder og anvendelser relateret dertil | |
| DK2638149T3 (da) | Immortalisering af epitelceller og fremgangsmåder til anvendelse | |
| DK2254598T3 (da) | Kombination af alfa 7-nikotinagonister og antipsykotika | |
| EP2619816A4 (en) | NANO WIRE POLYMER COMPOSITE ELECTRODES | |
| BR112012016793A2 (pt) | compostos tipo fumagilol e métodos de fazer e usar os mesmos | |
| DK2531181T3 (da) | Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf | |
| EP2515946A4 (en) | NANOCONJUGATE AND NANOCONJUGATE FORMULATIONS | |
| DK2647068T3 (da) | Batterielektrode og metode til fremstilling af samme | |
| DK3011975T3 (da) | Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf | |
| EP2306823A4 (en) | 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF | |
| FR2940608B1 (fr) | Utilisation de monosaccharides et composition | |
| DK2917358T3 (da) | Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater | |
| DK2358714T3 (da) | Alkylcyclohexylethere af dihydrotetraazabenzoazulener |